Janssen Submits Application to the European Medicines Agency (EMA) to Expand Use of DARZALEX®▼ (daratumumab) to Include Combination with Standard of Care Regimens
Janssen Submits Application to the European Medicines Agency (EMA) to Expand Use of DARZALEX®▼ (daratumumab) to Include Combination with Standard of Care Regimens
